
WHAT IS CLAIMED IS:

1. Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:


the Compound (A) has the structure:




(A); and

the one or more of Compound (B) is selected from the group consisting of a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor, or a pharmaceutically acceptable salt of any of the foregoing;


wherein the CDK4/6 inhibitor is selected from the group consisting of




,



,











and





, or a pharmaceutically acceptable salt of any of the foregoing;









wherein the selective aromatase inhibitor is selected from the group consisting of

, , , ,  and , or a pharmaceutically acceptable salt of any of the foregoing;





wherein the non-selective aromatase inhibitor is selected from the group consisting of  and , or a pharmaceutically acceptable salt of any of the foregoing;








wherein the mTOR inhibitor is selected from the group consisting of





, ,










,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;

wherein the PI3K inhibitor is selected from the group consisting of









,

,

,

,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;









wherein the ERK or the MEK inhibitor is selected from the group consisting of

,

,

,

,



,

,

,

,

,

, KO-947,

and

, or a pharmaceutically acceptable salt of any of the foregoing;

wherein the AKT inhibitor is selected from the group consisting of


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;


wherein the BET inhibitor is selected from the group consisting of


,

,

,

,

,

,

,

and




, or a pharmaceutically acceptable salt of any of the foregoing; and


wherein the Aurora inhibitor is selected from the group consisting of




,




,




,










,



,




,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

2. Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (C), or a pharmaceutically acceptable salt thereof, and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

the Compound (C) has the structure:



(C);

wherein:

X^1, Y^1 and Z^1 are each independently C or N;

with the first proviso that at least one of X^1, Y^1 and Z^1 is N;

with the second proviso that each of X^1, Y^1 and Z^1 is uncharged;

with third proviso that two of the dotted lines indicate double bonds;

with the fourth proviso that the valencies of X^1, Y^1 and Z^1 can be each independently satisfied by attachment to a substituent selected from H and R^{12};

X^2 is O;

A^1 is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^1 is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C_{1-6} alkyl), an optionally substituted cycloalkenyl(C_{1-6} alkyl), an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl);

R^2 and R^3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl and an optionally substituted C_{1-6} haloalkyl; or R^2

and R^3 together with the carbon to which R^2 and R^3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;


R^4 and R^5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl and an optionally substituted C_{1-6} haloalkyl; or R^4 and R^5 together with the carbon to which R^4 and R^5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;

R^6, R^7, R^8 and R^9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;

R^{10} is hydrogen, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;

R^{11} is hydrogen; and





R^{12} is hydrogen, halogen, an optionally substituted C_{1-3} alkyl, an optionally substituted C_{1-3} haloalkyl or an optionally substituted C_{1-3} alkoxy;

provided that the Compound (C) cannot be 







, or a pharmaceutically acceptable salt thereof; and

the one or more of Compound (B) is selected from the group consisting of a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, BET inhibitor and Aurora inhibitor, or a pharmaceutically acceptable salt of any of the foregoing;



wherein the CDK4/6 inhibitor is selected from the group consisting of:


,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;











wherein the selective aromatase inhibitor is selected from the group consisting of


,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;




wherein the non-selective aromatase inhibitor is selected from the group consisting of





and

, or a pharmaceutically acceptable salt of any of the foregoing;




wherein the mTOR inhibitor is selected from the group consisting of




,

,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing;

wherein the PI3K inhibitor is selected from the group consisting of












, , ,


, , ,

, , ,

 and , or a pharmaceutically acceptable salt of any of the foregoing;


wherein the ERK or the MEK inhibitor is selected from the group consisting of


,

,

,

,

,

,

,

,

,

, KO-947,

and




, or a pharmaceutically acceptable salt of any of the foregoing;


wherein the AKT inhibitor is selected from the group consisting of




,




,




,




,



,












and











, or a pharmaceutically acceptable salt of any of the foregoing;






wherein the BET inhibitor is selected from the group consisting of


,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing; and

wherein the Aurora inhibitor is selected from the group consisting of
















,

,

,

,

,

,

,

,














-61-



















,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.




3. The use of Claim 2, wherein for the Compound (C) when X^1 is NH; Y^1 and Z^1 are each C; A^1 is a phenyl, 2-fluorophenyl or 2,6-difluorophenyl; R^2 and R^3 are each methyl or one of R^2 and R^3 is hydrogen and the other of R^2 and R^3 is methyl; and R^4, R^5, R^6, R^7, R^8, R^9 and R^{10} are each hydrogen; then R^1 cannot be 2-hydroxyethyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 3-fluoro-2-methylpropyl, 3-hydroxy-2-methylpropyl or 2-fluoro-3-hydroxy-2-methylpropyl.

4. The use of Claim 2 or 3, wherein the Compound (C) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,


,

,

,

,

















,

,

,

,

,

,

,

,

,

,

,

,

,











,

,


,





,







,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.












5. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of ,




,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.











6. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.








7. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of

and

, or a pharmaceutically acceptable salt of any of the foregoing.



8. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of , , , , , , , ,  and , or a pharmaceutically acceptable salt of any of the foregoing.








9. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of , , , , , , , , , , and , or a pharmaceutically acceptable salt of any of the foregoing.



10. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of , ,










,

,

,

,

,

,

,

, KO-947,

and

, or a pharmaceutically acceptable salt of any of the foregoing.




11. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of , , , , ,  and , or a pharmaceutically acceptable salt of any of the foregoing.

12. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of , ,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

13. The use of any one of Claims 1-4, wherein the Compound (B) is selected from the group consisting of

,

,


,

,

,

,

,

,

,

,


,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

14. The use of any one of Claims 1-13, wherein the disease or condition is selected from the group consisting of a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, a vulvar cancer, a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, a Wilms' cancer, a skin cancer, a malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing's tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin's lymphoma, and a non-Hodgkin's lymphoma.

15. The use of any one of Claims 1-13, wherein the disease or condition is a breast cancer, a cervical cancer, an ovarian cancer, an uterine cancer, a vaginal cancer, and a vulvar cancer.

16. The use of Claim 15, wherein the disease or condition is a breast cancer.

17. The use of any one of Claims 14-16, wherein the breast cancer that does not include any point mutations ER mutations.

18. The use of any one of Claims 14-16, wherein the disease or condition is breast cancer that has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERα), wherein the mutation is selected from the group consisting of:

K303R, D538G, Y537S, E380Q, Y537C, Y537N, A283V, A546D, A546T, A58T, A593D, A65V, C530L, D411H, E279V, E471D, E471V, E523Q, E542G, F461V, F97L, G145D, G160D, G274R, G344D, G420D, G442R, G557R, H524L, K252N, K481N, K531E, L370F, L453F, L466Q, L497R, L536H, L536P, L536Q, L536R, L540Q, L549P, M388L, M396V, M421V, M437I, M522I, N156T, N532K, N69K, P147Q, P222S, P535H, R233G, R477Q, R503W, R555H, S282C, S329Y, S338G, S432L, S463P, S47T, S576L, V392I, V418E, V478L, V533M, V534E, Y537D and Y537H.

19. The use of any one of Claims 14-18, wherein the breast cancer is ER positive breast cancer.

20. The use of any one of Claims 14-18, wherein the breast cancer is ER positive/HER2-negative breast cancer.

21. The use of any one of Claims 14-20, wherein the breast cancer is local breast cancer.

22. The use of any one of Claims 14-20, wherein the breast cancer is metastatic breast cancer.

23. The use of any one of Claims 14-22, wherein the breast cancer is recurrent breast cancer.

24. The use of any one of Claims 14-23, wherein the breast cancer has been previously treated with an endocrine therapy.

25. The use of Claim 24, wherein the treatment was with a selective ER modulator (SERM).

26. The use of Claim 25, wherein the selective ER modulator is selected from the group consisting of tamoxifen, raloxifene, ospemifene, bazedoxifene, toremifene and lasofoxifene, or a pharmaceutically acceptable salt of any of the foregoing.

27. The use of Claim 24, wherein the treatment was with a selective ER degrader (SERD).

28. The use of Claim 27, wherein the selective ER degrader is selected from the group consisting of fulvestrant, (E)-3-[3,5-Difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid (AZD9496), (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol (elacestrant, RAD1901), (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-

(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid (Brilanestrant, ARN-810, GDC-0810), (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid (LSZ102), (E)-N,N-dimethyl-4-((2-((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)pyridin-2-yl)oxy)ethyl)amino)but-2-enamide (H3B-6545), (E)-3-(4-((2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid (rintodestrant, G1T48), D-0502, SHR9549, ARV-471, 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol (giredestrant, GDC-9545), (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid (SAR439859), N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine (AZD9833), OP-1250 and LY3484356, or a pharmaceutically acceptable salt of any of the foregoing.

29. The use of Claim 24, wherein the treatment was with an aromatase inhibitor.

30. The use of Claim 29, wherein the aromatase inhibitor is a steroidal aromatase inhibitor.

31. The use of Claim 30, wherein the steroidal aromatase inhibitor is selected from the group consisting of exemestane and testolactone, or a pharmaceutically acceptable salt of any of the foregoing.

32. The use of Claim 29, wherein the aromatase inhibitor is a non-steroidal aromatase inhibitor.

33. The use of Claim 32, wherein the non-steroidal aromatase inhibitor is selected from the group consisting of anastazole and letrazole, or a pharmaceutically acceptable salt of any of the foregoing.

34. The use of any one of Claims 14-22, wherein the breast cancer has not been previously treated.

35. The use of any one of Claim 14-34, wherein the breast cancer is present in a woman.

36. The use of Claim 35, wherein the subject is a premenopausal woman.

37. The use of Claim 35, wherein the subject is a perimenopausal woman.

38. The use of Claim 35, wherein the subject is a menopausal woman.

39. The use of Claim 35, wherein the breast cancer is present in a postmenopausal woman.

40. The use of any one of Claim 14-34, wherein the breast cancer is present a man.

41. The use of any one of Claim 14-40, wherein the breast cancer is present in a subject that has a serum estradiol level in the range of >15 pg/mL to 350 pg/mL.

42. The use of any one of Claim 14-40, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 15 pg/mL.

43. The use of any one of Claim 14-40, wherein the breast cancer is present in a subject that has a serum estradiol level ≤ 10 pg/mL.